Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
This advanced series brings together prominent figures in the breast cancer community to discuss the latest and emerging therapies.
Stay up to date with the latest ESMO recommendations on precision medicine for its optimal integration into daily care with this new webinar series.
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and get your questions answered by the ESMO Guidelines experts
Globally recognised experts in the field give their reasons why you should be part of this meeting, making strides in sarcoma and rare cancer care.
Stay up to date with the latest data in lung cancer and take part in this live discussion with international experts
The current state of the art in lung cancer therapy
All abstracts authors and titles are now online. Check what this multi-stakeholder forum has to offer and secure your seat!
Listen to international experts treating real-world cases and get valuable insights applicable to your daily practice.
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
Evidence for efficacy is based on the results from a Cohort 1 of the Study BLC3001
A phase II trial reports a longer recurrence-free and distant-metastasis free survival with the combination of mRNA and pembrolizumab.
New and updated recommendations from the ESGO–ESMO–ESP ovarian cancer consensus conference covering discussion of evolving data on pathology, molecular biology, and treatment of early-stage, advanced, and recurrent disease.
Availability of the ESMO Patient Guides translations in the Ukrainian language is further expending
ESMO has written to The Belgian Presidency of the Council of the European Union to express support for the development of an EU Directive to tackle work-related psychosocial risks and mitigate Europe’s health workforce crisis
The European Society for Medical Oncology (ESMO) will be represented at the Brussels conference on “Improving patient access to oncology medicines and the role of the EU HTA Regulation: an urgent call to action” to be held on 1 February
Findings from the EUROCARE-6
The European Society for Medical Oncology (ESMO), together with a number of health advocacy organisations, has published a statement condemning the European Commission’s decision to not bring forward the proposed Council recommendation on smoke-free environments.
Evidence for efficacy is based on the results from a Cohort 1 of the Study BLC3001
Findings from the EUROCARE-6
New indication concerns the treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory
Findings from a comprehensive genomic profiling and immunophenotypic characterisation
In few cases for which genetic sequencing has been performed to date, the CAR transgene has been detected in the malignant clone
Findings from a phase II study
Evidence for efficacy is based on the results from the KEYNOTE-A18 study
Findings from the final overall survival analysis of PALOMA-2 study
Findings from KEYNOTE-942 study
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas
Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
As the world observes Universal Health Coverage Day, ESMO anticipates the results of the latest study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines, highlighting a worrying stall over the last five years
The ESMO Award for Immuno-Oncology 2023 was bestowed to Steven A. Rosenberg in recognition of his exceptional contribution to the field of cancer immunology research.
After five days filled with practice-changing data, intense discussions and educational sessions addressing the needs and issues currently arising for oncology professionals and impacting patients with cancer worldwide, the ESMO Congress 2023 today sent home its more than 33,000 participants from 144 countries with plenty of food for thought and ample material to enrich their medical practice.
ESMO and ASCO, the two largest professional organisations for oncologists, have released the 2023 edition of their joint recommendations for the Curriculum for Training in Medical Oncology
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO expresses deep sorrow about all the ongoing tragic events that continue to happen in many parts of the world and joins the voices pressing for a rapid return to peace
We regret to inform you of an embargo breach in which late-breaking abstract data has been made available online ahead of the official publication schedule
A phase II trial reports a longer recurrence-free and distant-metastasis free survival with the combination of mRNA and pembrolizumab.
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
Acquired genomic changes, decreased TILs and HLA class I expression were identified in patients with non-small cell lung cancer progressing on immune checkpoint inhibitors
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Evidence is compelling, but utility may depend on the clinical context
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
From the 65th American Society of Hematology Annual Meeting:
Switching from brentuximab vedotin to nivolumab alongside chemotherapy increased progression-free survival and reduced toxicity in patients aged 60 years and older with classic Hodgkin’s lymphoma
From the 65th American Society of Hematology Annual Meeting:
Patients given zanubrutinib for relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma continue to have better PFS than their ibrutinib-treated counterparts after 3 years
From San Antonio Breast Cancer Symposium 2023:
Combining palbociclib plus fulvestrant with inavolisib significantly improves progression-free survival for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
South Africa
South Africa
Kenya
Kenya
Virtual Meeting
France
United Kingdom
Switzerland
Czech Republic
Brazil
Spain
Brazil
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
